The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A multicenter phase II trial of docetaxel, cisplatin and cetuximab (TPE) followed by cetuximab concurrent with radiotherapy in patients with local advanced squamous cell carcinoma of the head and neck (ECRIPS study).
 
Sadamoto Zenda
Honoraria - Eisai; Merck Serono; Nihonkayaku
 
Yosuke Ota
No Relationships to Disclose
 
Naomi Kiyota
Honoraria - Bayer; Bristol-Myers Squibb Japan; Eisai; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Boehringer Ingelheim; Ono Pharmaceutical
 
Susumu Okano
Honoraria - Merck Serono
 
Masato Fujii
Consulting or Advisory Role - Merck Serono
 
Morimasa Kitamura
No Relationships to Disclose
 
Shunji Takahashi
Honoraria - Astellas Oncology; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Chugai Pharma; Pfizer
Research Funding - AstraZeneca; Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tsutomu Ueda
No Relationships to Disclose
 
Nobuya Monden
No Relationships to Disclose
 
Takeharu Yamanaka
No Relationships to Disclose
 
Makoto Tahara
Honoraria - Bayer; Bristol-Myers Squibb; Eisai; Merck Serono; Takeda
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)